O-(2-氨基乙基)-O'-(2-叠氮乙基)戊乙二醇 | 957486-82-7

• 物质功能分类: 催化剂及助剂 - 聚乙二醇衍生物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: O-(2-氨基乙基)-O'-(2-叠氮乙基)戊乙二醇
• 中文别名: 氨基-六聚乙二醇-叠氮
• 英文名称: 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine
• 英文别名: O-(2-aminoethyl)-O'-(2-azidoethyl)-pentaethylene glycol；Azido-PEG6-amine；2-[2-[2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanamine
• CAS: 957486-82-7
• 化学式: C₁₄H₃₀N₄O₆
• 分子量: 350.415
• InChiKey: VCQSTKKJKNUQBI-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于水、DMSO、DCM、DMF

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  24
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  95.8
• 氢给体数：
  1
• 氢受体数：
  9

安全信息

• WGK Germany：
  3
• 海关编码：
  2929909090
• 储存条件：
  2-8℃

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
: O-(2-Aminoethyl)-O′-(2-azidoethyl)pentaethylene
Product name
glycol
CAS-No. : 957486-82-7
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Azido-PEG-amine (n=6)
Formula : C14H30N4O6
Molecular Weight : 350,41 g/mol
Component Concentration
O-(2-Aminoethyl)-O'-(2-azidoethyl)pentaethylene glycol
CAS-No. 957486-82-7 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Normal measures for preventive fire protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Recommended storage temperature: 2 - 8 °C
Store under inert gas. Air sensitive.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Azido-PEG6-amine 是一种 PROTEolisome-activating receptor (PROTAC) 连接子，属于聚乙二醇（PEG）类。它可用于合成 PROTAC 分子。此外，Azido-PEG6-amine 也是一种不可降解的含六个单元 PEG 的抗体偶联药物 (ADC) 连接子。

靶点

| PEGs | Non-cleavable |

体外研究

PROTAC 分子包含两种不同配体，一种用于与 E3 泛素连接酶结合，另一种用于与靶蛋白结合。PROTAC 利用细胞内的泛素-蛋白酶体系统选择性地降解目标蛋白质。

抗体偶联药物 (ADC) 由通过连接子（ADC linker）连接到抗体上的 ADC 细胞毒性剂组成。

反应信息

• 作为反应物：
  描述：

  O-(2-氨基乙基)-O'-(2-叠氮乙基)戊乙二醇 在 copper(II) sulfate 、 sodium ascorbate 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 三[(1-苄基-1H-1,2,3-三唑-4-基)甲基]胺 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 生成 (3S)-3-[[4-[[1-[2-[2-[2-[2-[2-[2-[2-[[(2S)-2-cyclohexyl-2-[[(2S)-3-cyclohexyl-2-(1,2-oxazole-5-carbonylamino)propanoyl]amino]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]triazol-4-yl]methoxy]benzoyl]amino]-4-[4-[3-[(4-methoxypyridin-2-yl)amino]propoxy]phenyl]butanoic acid
  参考文献：
  名称：

  Synthesis and initial pharmacology of dual-targeting ligands for putative complexes of integrin αVβ3 and PAR2

  摘要：

  首次描述了针对蛋白酶活化受体（PARs）和整合素的双靶向配体示例，具有潜在的抗炎应用。

  DOI：

  10.1039/d0md00098a

文献信息

• [EN] ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS<br/>[FR] ANTICORPS CONÇUS COMME AGENTS DE DÉGRADATION MOLÉCULAIRE PAR L'INTERMÉDIAIRE DE RÉCEPTEURS CELLULAIRES
  申请人：UNIV YALE

  公开号：WO2021072246A1

  公开（公告）日：2021-04-15

  The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.

  本公开提供了一种双功能化合物，可用于促进或增强特定循环蛋白的降解。在某些实施例中，循环蛋白在受试者中介导疾病和/或紊乱，治疗或管理该疾病和/或紊乱需要降解、去除或减少受试者中循环蛋白的浓度。因此，在某些实施例中，将本公开的化合物给予受试者可去除或减少循环蛋白的循环浓度，从而治疗、改善或预防疾病和/或紊乱。
• [EN] RAPAMYCIN ANALOGS AS MTOR INHIBITORS<br/>[FR] ANALOGUES DE LA RAPAMYCINE UTILISÉS EN TANT QU'INHIBITEURS DE MTOR
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2018204416A1

  公开（公告）日：2018-11-08

  The present disclosure relates to rapamycin analogs of the general Formula (I). The compounds are inhibitors of mTOR and thus useful for the treatment of cancer, immune-mediated diseases and age related conditions.

  本公开涉及一般式（I）的雷帕霉素类似物。这些化合物是mTOR的抑制剂，因此对于治疗癌症、免疫介导性疾病和与年龄相关的疾病是有用的。
• Glycosylated Reversible Addition–Fragmentation Chain Transfer Polymers with Varying Polyethylene Glycol Linkers Produce Different Short Interfering RNA Uptake, Gene Silencing, and Toxicity Profiles
  作者：Elizabeth G. L. Williams、Oliver E. Hutt、Tracey M. Hinton、Sophie C. Larnaudie、Tam Le、James M. MacDonald、Pathiraja Gunatillake、San H. Thang、Peter J. Duggan

  DOI：10.1021/acs.biomac.7b01168

  日期：2017.12.11

  Achieving efficient and targeted delivery of short interfering (siRNA) is an important research challenge to overcome to render highly promising siRNA therapies clinically successful. Challenges exist in designing synthetic carriers for these RNAi constructs that provide protection against serum degradation, extended blood retention times, effective cellular uptake through a variety of uptake mechanisms, endosomal escape, and efficient cargo release. These challenges have resulted in a significant body of research and led to many important findings about the chemical composition and structural layout of the delivery vector for optimal gene silencing. The challenge of targeted delivery vectors remains, and strategies to take advantage of nature’s self-selective cellular uptake mechanisms for specific organ cells, such as the liver, have enabled researchers to step closer to achieving this goal. In this work, we report the design, synthesis, and biological evaluation of a novel polymeric delivery vector incorporating galactose moieties to target hepatic cells through clathrin-mediated endocytosis at asialoglycoprotein receptors. An investigation into the density of carbohydrate functionality and its distance from the polymer backbone is conducted using reversible addition–fragmentation chain transfer polymerization and postpolymerization modification.

  实现短干扰RNA（siRNA）的高效和靶向递送是克服的一个重要研究挑战，以使前景广阔的siRNA疗法在临床上成功。设计合成输送载体以保护这些RNA干扰构件免受血清降解、延长血液滞留时间、通过多种摄取机制有效细胞摄取、内吞体逃逸和高效货物释放仍然存在挑战。这些挑战促成了大量研究，并导致了关于递送载体化学成分和结构布局的重要发现，以实现最佳基因沉默。靶向递送载体的挑战仍然存在，利用自然自选择性细胞摄取机制（针对特定器官细胞，例如肝脏）的方法使研究人员更接近实现这一目标。在这项工作中，我们报告了一种新型聚合物递送载体的设计、合成和生物评估，该载体通过结合半乳糖基团，通过粘附蛋白介导的内吞作用靶向肝细胞，并与天冬氨酸糖蛋白受体结合。通过可逆加成-断裂链转移聚合和聚合后修饰，研究了碳水化合物功能密度及其与聚合物骨架之间的距离。
• METHODS AND COMPOSITIONS FOR PROTEIN LABELLING
  申请人：Gill Herman

  公开号：US20100221176A1

  公开（公告）日：2010-09-02

  A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18 F into proteins with 18 F labelling reagents.

  提供了一个模块化平台，用于快速准备各种水溶性假体基团，能够有效地将 18 F引入蛋白质中，使用 18 F标记试剂。
• Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization
  作者：Mark W. Majewski、Disha M. Gandhi、Ricardo Rosas、Revathi Kodali、Leggy A. Arnold、Chris Dockendorff

  DOI：10.1021/acsmedchemlett.8b00538

  日期：2019.1.10

  based upon reported antagonists for the subtypes PAR1 and PAR2. Modified versions of the PAR1 antagonist RWJ-58259 containing alkyne adapters were connected via cycloaddition reactions to azide-capped polyethylene glycol (PEG) spacers attached to imidazopyridazine-based PAR2 antagonists. Initial studies of the PAR1-PAR2 antagonists indicated that they inhibited G alpha q-mediated calcium mobilization in

  基于已报道的针对亚型PAR1和PAR2的拮抗剂，已经制备了靶向推定的蛋白酶激活受体（PAR）异聚体的新型二价配体。包含炔连接体的PAR1拮抗剂RWJ-58259的改良版通过环加成反应与连接至基于咪唑并哒嗪的PAR2拮抗剂的叠氮基封端的聚乙二醇（PEG）间隔基连接。对PAR1-PAR2拮抗剂的初步研究表明，它们在PAR1和PAR2激动剂驱动的内皮细胞和癌细胞中抑制Gαq介导的钙动员。这种新型化合物有望预防再狭窄，癌细胞转移和其他增生性疾病。